Navigation Links
FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
Date:3/11/2008

g-Plough announced that the FDA assigned priority review status to the company's New Drug Application (NDA) for sugammadex. In the U.S., priority review is granted to drugs that FDA believes will provide meaningful benefit over existing treatment options.

Sugammadex is specifically designed to reverse the effects of certain widely used muscle relaxants, marketed in the United States as ZEMURON(R) (rocuronium bromide) and vecuronium bromide. Muscle relaxants are used as part of general anesthesia during surgical procedures. Sugammadex works in an entirely novel way to encapsulate the muscle relaxant molecule and restore muscle function so that patients can breathe on their own again. Reversal with sugammadex is generally rapid and can even be used in emergency situations when immediate reversal of rocuronium is needed.

Schering-Plough acquired sugammadex through its combination with Organon BioSciences on November 19, 2007.

About Sugammadex

Sugammadex is a novel selective relaxant binding agent (SRBA) under development by Organon, a part of Schering-Plough Corporation. Sugammadex was designed to reverse the effects of rocuronium bromide (ZEMURON/ESMERON(R)/ESLAX(R)) or vecuronium bromide, muscle relaxants commonly used during surgeries that require profound muscle relaxation. Anesthesiologists use muscle relaxation to improve surgical conditions, to facilitate intubation and mechanical ventilation, and to reduce the chance of complications.

In clinical trials to date, sugammadex has demonstrated the ability to rapidly reverse shallow and profound depths of rocuronium-induced muscle relaxation, thereby enabling control of the onset and offset of skeletal muscle relaxation through the use of both drugs(1). Sugammadex also has demonstrated the ability to reverse the effects of muscle relaxation induced by vecuronium bromide. The most common adverse reactions (incidence >5%) seen with sugammadex in clinical trials were anesthetic compli
'/>"/>

SOURCE Schering-Plough
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
2. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
3. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
4. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
7. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
8. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
9. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
10. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
11. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Boston Children,s Hospital,s Global Pediatric Summit + Awards, ... "Innovation Tank" – a forum designed to give pediatric ... or product solution to a panel of acclaimed judges ... accelerate the innovation and bring it to market. ... 31, will be moderated by Daymond John ...
(Date:7/24/2014)... 24, 2014  Bruin Biometrics (BBI), a pioneer ... after two weeks of clinical briefings to over ... it gained substantial concurrence on both the clinical ... utility of BBI,s SEM Scanner. ... the respondents drawn from the European Wound Management ...
(Date:7/24/2014)... N.J. , July 24, 2014  Bayer ... III trial that evaluated a 15% foam formulation ... topical treatment of inflammatory papules and pustules of ... treatment option to complement the currently available AzA ... causing inflammatory lesions (papules and pustules) as well ...
Breaking Medicine Technology:Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3Bruin Biometrics Secures Support of EU Scientific Community for its SEM Scanner Technology 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 3
... The Leukemia & Lymphoma,Society has awarded a $550,000 ... Wilmot Cancer Center at the University of Rochester Medical,Center. ... funding the first two years of the five-year program., ... will support,Dr. Friedberg,s work on a new targeted treatment ...
... Assay Submitted for FDA Clearance, SAN DIEGO, July ... and Company) (NYSE: BDX ), announced today the ... the rapid diagnosis,of patients with Clostridium difficile infection (CDI). ... simplicity and speed in one test,procedure. BD has also ...
Cached Medicine Technology:University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society 2BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections 2BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections 3
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & ... (Swine, Poultry, Cattle, Pets, Aquaculture, and Others) - Global ... feed palatability enhancers & modifiers market with an analysis ... value, of types of feed flavors, sweeteners, and text ... figures spread through 275 pages and in-depth TOC on ...
(Date:7/24/2014)... increases your risk of death, but recessions decrease ... While previous studies of individuals have shown that ... mortality rate, more comprehensive studies have shown, unexpectedly, ... increase. Researchers from Drexel University and the University ... better understand these seemingly contradictory findings. , Using ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 While healthcare ... in providing quality interpretation services to non-English speakers within ... down. According to Common Sense Advisory, the language ... to $2.3 billion in 2016 (1); additionally, officials at ... to shift over to video remote interpreting ...
(Date:7/24/2014)... known as neonicotinoids, were found commonly in streams ... study. This is the first broad-scale investigation of ... one of the first conducted within the United ... of insect pests, use of neonicotinoid insecticides has ... United States, particularly in the Midwest. The ...
(Date:7/24/2014)... Dr. Kwame Bawuah Edusei, a diplomat, entrepreneur, medical ... to the youth to persevere in their endeavors to ... the youth to stay away from social vices and ... will afford you the opportunity of acquiring life surviving ... in your career path.” Professionals in the fields of ...
Breaking Medicine News(10 mins):Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4Health News:Joblessness could kill you, but recessions could be good for your health 2Health News:Joblessness could kill you, but recessions could be good for your health 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 2Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 4Health News:Corn & soy insecticides similar to nicotine found widespread in Midwest rivers -- USGS news 2Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2
... aid in understanding ADD and more , FRIDAY, Aug. 28 ... a crowd, it appears that your "mind,s eye" acts like ... until you find the right person. , Researchers from the ... as they searched for a specific tilted, colored bar among ...
... 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: ... announced today that,the Beijing Public Health Bureau has selected ... Sinovac,s seasonal influenza vaccine, for,the benefit of the citizens ... process for the purchase of flu vaccines and,corresponding services ...
... , HARBIN, China, Aug. 28 ... Medical" or "the Company") (Nasdaq: CSKI ), ... People,s Republic of China ("PRC"), today announced that the,Company,s ... Thursday,September 24, 2009 at Harbin Shen Te Hotel which ...
... ... , ... (PRWEB) August 28, 2009 -- Promising cancer research treatment breakthrough seeks funding for corroboration., ... CHAI Foundation , a small 501(c)(3) non-profit medical research organization seeking to find ...
... , TOKYO, Aug. 28 ALOKA CO., ... generation of compact color ultrasound systems. This new multi-purpose system, ... fully upgradable and easy to use. , , ... ProSound Alpha 10 and Alpha 7, the ProSound Alpha 6 ...
... , TOSU, Saga, Japan and MIAMI, Aug. ... Inc. today announced the completion of their acquisition of Noven Pharmaceuticals, ... Inc., a wholly owned subsidiary of Hisamitsu U.S., Inc., with and ... the Agreement and Plan of Merger among the companies, at the ...
Cached Medicine News:Health News:Brain May Use Its 'Mind's Eye' to Control Chaos 2Health News:Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 2Health News:Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 3Health News:China Sky One Medical, Inc. to Hold Annual Meeting of Shareholders on September 24, 2009 2Health News:China Sky One Medical, Inc. to Hold Annual Meeting of Shareholders on September 24, 2009 3Health News:Promising Cancer Research Treatment Breakthrough Seeks Funding for Corroboration of Results 2Health News:ALOKA Announces New ProSound Alpha Series Ultrasound System 2Health News:ALOKA Announces New ProSound Alpha Series Ultrasound System 3Health News:Hisamitsu Pharmaceutical Completes Acquisition of Noven Pharmaceuticals 2
Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....
This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption....
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... Myeloperoxidase IgG ELISA test system is intended ... IgG-class antibody to myeloperoxidase in human serum. ... used as an aid in the diagnosis ... elevated levels of anti-neutrophil cytoplasmic antibodies (ANCA). ...
Medicine Products: